Recent Articles
Merck Is Shopping for Smarts In Hep C
Jan. 13, 2012, 7:30 am EDT – The pharma giant says it's determined to be the leader in treatments for the disease -- a market that is expected to hit $20 billion by 2020. More
Idenix and Achillion Jump on Takeover Talk
Jan. 10, 2012, 12:28 pm EDT – Their hepatitis C drugs could be lures for Big Pharma after a rival gets a juicy offer from Bristol-Myers Squibb. More
Why Disposing of Stericycle Shares May Be Right Move
Jan. 10, 2012, 6:00 am EDT – Despite dropping by more than 10% since October, Stericycle shares still have more room below it. But the company does have a few options to reassure investors. More
Dendreon Jumps 40% on Provenge Sales
Jan. 5, 2012, 3:51 pm EDT – Dendreon saw its stock jump Thursday as sales of its cancer drug beat the expectations of both analysts and the company itself. More
Teva’s New CEO Is Battle-Tested. Good Thing
Jan. 4, 2012, 2:06 pm EDT – Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker. More
Mead Johnson Bounce Followed J&J Script
Jan. 4, 2012, 9:40 am EDT – Mead Johnson's recent Enfamil scare sent many investors packing -- but those who stuck with the stock could soon be rewarded. More
FDA, Insurers Demand Tests for New Drugs
Jan. 3, 2012, 11:51 am EDT – Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for "companion diagnostics." More
2011′s Best and Worst Picks From InvestorPlace’s Barry Cohen
Dec. 28, 2011, 10:59 am EDT – Barry Cohen discusses some of his picks from 2011 -- and how that will affect his take on companies moving forward. More
Walgreen Not Sweating Loss of Express Scripts Customers to CVS — Should It Be?
Dec. 22, 2011, 8:40 am EDT – CVS says it could gobble up to 23M prescriptions that Walgreens has sold through Express Scripts if a deal isn't announced. So far, WAG is sticking to its guns. More
Ariad Pharmaceuticals Still Might Have Upside
Dec. 21, 2011, 12:34 pm EDT – Ariad Pharmaceuticals is up 120% in the past 12 months, mostly fueled on optimism over its trial leukemia treatment. But some analysts think the ceiling is higher. More
